Analysis Of200Patients With Advanced Non-small Cell Lung Cancer Chemotherapy Efficacy And Prognostic Factors

Purpose: A retrospective analysis of200patients with advanced NSCLC(non-small cell lung cancer) patients with clinical data features, explore the impact ofadvanced NSCLC chemotherapy and prognostic factorsMethods: Collection2005.1.1-2012.7.1Liaoning Provincial Tumor Hospital, thefirst confirmed diagnosis of advanced NSCLC patients hospitalized clinical data,medical records rigorous screening and summarized according to the inclusion criteriaand exclusion criteria; Chemotherapy (gemcitabine He Bin+cisplatin (GP), vinorelbine+cisplatin (NP), paclitaxel+cisplatin (TP)), age, gender, ECOG score, pathologicaltype, clinical stage, smoking history, the first clinic lung metastases, the first diagnosisof pleural effusion and first-line chemotherapy efficacy factors such as the clinical datastratification. SPSS16.0statistical analysis software, the percentage of the medianmethod to describe the clinical data, the influencing factors of the efficacy ofchemotherapy group were compared using chi-square test. Kaplan-Meier, Log-Rankunivariate and multivariate Cox stepwise regression model for survival analysis.Result：200cases of advanced NSCLC patients; chemotherapy:①GP program83cases of10(41.5),(2) NP program99cases of10(49.5),③TP program18cases of(9%); Age:①<70years of age in170cases (85%),②≥70years,30patients (15%);gender:(1) male and131(65.5%), the②female69cases (34.5%); ECOG performancestatus:(1)0-1points,103cases (51.5%),②2minutes97cases (48.5%); histologicaltypes: squamous cell carcinoma84cases (42%), adenocarcinoma in116cases (58%);clinical stages:(1) Ⅲ b of62patients (31%), the②IV of138cases (69%); history ofsmoking: Smoking106cases (53%), non-smoking94cases (47%); First diagnosis oflung metastases:(1) lung metastasis in21cases (10.5%),②lung metastasis combinedwith other parts of the transfer of34cases (17%),(3) other parts of the transfer of145 cases (72.5%); first diagnosis of pleural effusion:(1) pleural solution of26cases (13%),the The②pleural effusion metastases in44patients (22%),(3) other parts of thetransfer of130patients (65%). First-line chemotherapy:(1) CR group0cases,88cases(44%)(2) PR group,③SD group and62(31%), the the④PD group of50patients(25%); To the end of follow-up,161patients (80.5%) died, survival in29cases (14.5%),10patients were lost (5%). All patients were first diagnosed, have not receivedchemotherapy and surgical treatment. Advanced NSCLC patients with1-,2-, and3-year survival rates were47.5%,13.5%,8.4%, the median survival time was11.4months. Chemotherapy, age, gender, ECOG score, pathological type, clinical stage andsmoking history and other factors on the efficacy of chemotherapy no significantdifference. Univariate analysis showed: age, first diagnosed lung metastases, Firstdiagnosis of pleural effusion and first-line chemotherapy of advanced NSCLCprognosis relevant. Chemotherapy, gender, ECOG score, pathological type, clinicalstage and smoking history affect the survival of patients with advanced NSCLC nosignificant difference. Cox multivariate survival analysis in single factors in advancedNSCLC factors: first-line chemotherapy are independent prognostic factors of advancedNSCLCConclusion: First-line chemotherapy for advanced NSCLC independentprognostic factors, the PR group than in the PD group prognosis is better. The firstdiagnosis of lung metastases compared with other parts of the transfer of advancedNSCLC patients with good prognosis. The first diagnosis of pleural effusion comparedwith other parts of the transfer of advanced NSCLC and poor prognosis.